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The dimerization of different PDZ domains suggests that these protein modules evolved to guide the
assembly of multiprotein complexes. In this issue, Chang et al. (2011) describe amassively parallel approach
for identifying all PDZ dimerization events that reveals the prevalence of this protein-protein interaction.Protein-protein interactions are instru-
mental in guiding the assembly of com-
plexes that perform most of the critical
molecular processes in the cell. Protein-
protein interactions can either be essential
for assembling catalytically active com-
plexes from individual poypeptides that
have no independent activity or drive the
associations of regulatory or accessory
factors with a protein displaying a partic-
ular catalytic activity. Some of the most
common examples of large molecular
machines built from a number of different
protein and other components include
the DNA replication complex, the ribo-
some forprotein synthesis, and theprotea-
some for molecular degradation (Hartwell
et al., 1999). Many other protein-protein
interactions are dynamic and regulated
by posttranslational modifications such
as protein phosphorylation found in, for
example, the signal transduction path-
ways that transmit extracellular signals to
the nucleus, resulting in changes in gene
expression. (Oda et al., 2005).
The sequencing of many genomes,
coupled with a great deal of fundamental
research, hasmade it clear that there exist
a number of relatively small domains that
specialize in mediating protein-protein in-
teractions. One of the most common of
these protein interaction modules is the
PDZ domain, which is constituted of
approximately 80–90 residues. PDZ do-
mains recognize a short stretch of 5–7
amino acids usually at the carboxyl
terminus of its partner protein (Songyang
et al., 1997), which is most commonly
a transmembrane receptor or an ion chan-
nel. Thus, the PDZ domain aids in local-
izing these proteins to specific sub-
cellular regions, leading to the formation
ofmultiprotein complexes tomediate pro-
cesses such as cell signaling. In addition
to this canonical binding mode, there
have been a few observations of stabledimers of two different PDZ domains.
One example of such an interaction is the
PDZ domain of neuronal nitric oxide syn-
thase (nNOS), which interacts specifically
with the PDZ domain of a1-syntrophin
(Hillier et al., 1999). The physiological
relevance of this association is to localize
nNOS in the dystrophin complex of mus-
cle cells, thereby coupling NO production
tomuscle contraction.Hence, theproduc-
tion of NO increases blood flow, compen-
sating for the exertion of muscle con-
traction (Hillier et al., 1999). Given this
precedent, one can suspect that there
are many more important PDZ-PDZ in-
teractions in cells that have yet to be
elucidated.
In the current issue of Chemistry &
Biology, Chang et al. (2011) have com-
pleted the arduous task of surveying all
of the PDZ dimerization partners across
the mouse proteome. Every PDZ domain
encoded in the mouse genome (157 in
total) was cloned, expressed, purified,
and printed onto a glass microarray.
Microarray technology is ideal for large-
scale screening because it enables many
different samples, in this case PDZ do-
mains, to be analyzed rapidly and simulta-
neously, as well as allowing for the ex-
periment to be repeated under varying
conditions. MacBeath and Schreiber
(2000) have successfully developed func-
tional protein microarrays that attach the
protein of interest to surface of the slide
covalently but maintain the protein’s
native properties, including the ability to
interact specifically with other proteins.
The PDZ domain microarray was incu-
bated with each of the 157 different
mouse PDZ domains and analyzed to
determine whether each PDZ domain
bound specifically to any of other PDZ
domains within the proteome. This re-
sulted in the identification of approxi-
mately 300 PDZ-PDZ interactions.Chemistry & Biology 18, September 23, 2011 ªThe positive hits from the protein
microarray were validated using solution-
phase fluorescence polarization. Fluores-
cence polarization is a versatile technique
to measure equilibrium binding that is
highly sensitive, reproducible, and re-
quires modest quantities of sample,
thereby providing a rapid means to char-
acterize the binding affinities of each of
the PDZ domain interactions (Heyduk
et al., 1996). From the fluorescence polar-
ization results, 15 PDZ domain interac-
tions were identified with a KD <5 mM.
Although low micromolar affinity interac-
tions between two purified protein do-
mains are observed in isolation, these
interactions may not be relevant in the
significantly more complex cellular envi-
ronment. Therefore, the PDZ domains
observed to dimerize in the fluorescence
polarization assay were returned to the
context of their full-length proteins, and
the interactions were analyzed in a cel-
lular environment using coaffinity purifica-
tion (coAP). Gratifyingly, the coAP assays
scored positive for all seven novel protein-
protein interactions that were tested.
Furthermore, these novel interactions
occurred mostly between proteins that
not only exist in the same cellular compo-
nent, but are also connected to each
other through broader protein networks.
Overall, Chang et al. (2011) report
37 PDZ-PDZ interactions involving 46
distinct PDZ domains, suggesting that
this binding mode occurs at a higher
frequency than previously suspected.
This noncanonical interaction may have
evolved to guide the assembly of, or to
strengthen, multiprotein complexes. For
instance, a new PDZ-PDZ interaction
between CASK and Pard3 was identified
in this work. Both proteins are involved
in the epithelial cell junction network
and were postulated to interact only in-
directly through other protein-mediated2011 Elsevier Ltd All rights reserved 1071
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Previewsinteractions. Specifically, CASK is known
to interact with ZO1, which interacts with
JAM2, which interacts with Pard3, thus
bringing CASK and Pard3 into proximity.
However, the work presented here shows
that CASK and Pard3 interact directly
through dimerization of their PDZ do-
mains. Why these two proteins interact
directly requires further investigation, but
now that Chang et al. (2011) have identi-
fied every PDZ-PDZ interaction from the
mouse proteome, they have paved the1072 Chemistry & Biology 18, September 23,way for establishing the biological signifi-
cance of these interactions.REFERENCES
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Casein lytic peptidase P (ClpP) is a serine peptidase that, when coupled to its cognate ATPase, facilitates the
controlled degradation of both damaged and unwanted proteins in bacteria. In this issue of Chemistry &
Biology, Leung et al. (2011) report a small molecule screen against ClpP, fromwhich they identified four struc-
turally distinct compounds that activate ClpP for unregulated proteolysis.The treatment of bacterial infections with
antimicrobial drugs was one of the most
profound medical advances of the last
century. The discovery of these drugs
began in the 1930s and continued
unabated over the next four decades.
Indeed, many of the drugs we use today
can be traced back to natural compounds,
identified during these ‘‘golden’’ years of
drug discovery, and their effectiveness is
evidenced by our current quality of life.
However,since theendof this fruitful period
of drug discovery, relatively few new
compounds (natural or synthetic) have
beendeveloped.Concomitantly,especially
during the last decade, there has been a
concerning increase in the occurrence of
nosocomial infections involving drug resis-
tant bacterial species (e.g., Methicillin-
resistant Staphylococcus aureus [MRSA]
and Vancomycin-resistant Enterococi
[VRE]) (Levy and Marshall, 2004) that has
in turn lead to the emergence of multi-
drug resistant (MDR)bacteria.Hence, there
is a real need for the development of new
drugs, especially those that target novel
mechanisms to kill bacterial cells.In 2005, Bro¨tz-Oesterhelt and col-
leagues identified a new class of natural
antibiotics termed acyldepsipeptides
(ADEPs) that showed remarkable pro-
mise, as they were active in the treatment
of rodents infectedwith antibiotic resistant
bacteria (Bro¨tz-Oesterhelt et al., 2005).
Surprisingly, these compounds do not kill
bacteria by inhibiting an essential cellular
process, but rather they target a non
essential protein, the peptidase ClpP, to
kill bacteria. Indeed ADEPs are proposed
to kill bacteria via a unique mechanism—
by triggering the widespread and unregu-
lateddegradationof nascentpolypeptides
and unfolded proteins (Kirstein et al.,
2009). Despite their remarkable bacteri-
cidal activity, limited availability of these
antibiotics has hampered progress in
elucidating their mechanism of action;
hence the identification of new ClpP acti-
vators of unregulated proteolysis may aid
in further defininghow this promising class
of drug functions.
ClpP is a barrel-shaped protein com-
posed of two heptameric rings in which
the catalytic residues are sequesteredinside a proteolytic chamber. In the
absence of its cognate AAA+ (ATPase
associated with various cellular activities)
component (e.g., ClpA, ClpC or ClpX),
entry into this chamber is restricted to
a narrow entry portal at either end of the
complex (Wang et al., 1997). In this state,
although short peptides can enter the
proteolytic chamber for hydrolysis, large
polypeptides are generally excluded
from the chamber, preventing the indis-
criminate degradation of cellular proteins.
Therefore, in the absence of its cognate
ATPase, protein degradation by ClpP is
effectively turned OFF (Figure 1). By con-
trast, in the presence of its cognate
ATPase, ClpP-mediated protein degrada-
tion is turned ON (Figure 1). Currently, it is
widely accepted that activation of ClpP
results from docking of a specific loop
(known as the IGF loop) on the cognate
ATPase (Kim et al., 2001), which culmi-
nates in opening of the narrow entry portal
located at the distal ends of the complex,
supporting entry of unfolded polypep-
tides, into the proteolytic chamber (Bur-
ton et al., 2001).
